NCT01821079View on ClinicalTrials.gov

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Healthy
Interventions
DRUG

PF-05175157

Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)

DRUG

PF-05175157

Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

DRUG

PF-05175157

Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

DRUG

PF-05175157

Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01821079 - A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation | Biotech Hunter | Biotech Hunter